Yours, Dorothy* In the 1970s, a number of "new" diseases were discovered, most of which were known but had been poorly defined in the past. Such "new" diseases included infant botulism; Legionnaire's disease; Pneumocystis carinii pneumonia in the immunosuppressed; Clostridium difficile toxin-associated, antibiotic-induced pseudomembranous colitis; and rotavirus, yersinia, and campylobacter as agents of acute diarrhea. Group B streptococcus (GBS) was recognized as an agent of human disease in the 1930s [1, 2] , but it has clearly grown in importance during the 1970s. Unlike these other agents, the type of disease and spectrum of common syndromes caused by GBS were apparent to some investigators prior to the 1970s [3] , but, as in the case of these "new diseases," research stimulated by an alarming increase in incidence has revolutionized our concept of the pathogenesis of the disease. Despite this new information, we are still unable to account for the rise in incidence which resulted in a worldwide pandemic of neonatal sepsis and meningitis due to this agent.
Clearly the increase in group B streptococcal infections of infants is not a matter of increased recognition but of increased incidence. The causative agent had been isolated and identified using routinely available media and methods long before the 1970s [3] and longitudinal observations at several institutions where neonatal sepsis 291 *Excerpt from a note to the author from Dr. Horstmann on receiving a reprint of [4] . Copyright [4] and the vast majority had life-threatening sepsis [5] . At Yale the highest incidence of GBS infection was seen in 1977 (Table 1 ) and the incidence had only declined slightly by the end of the decade.
MORE QUESTIONS THAN ANSWERS In 1973 [6] and again in 1976 [7] , the clinical experience at Yale with GBS neonatal infections was reviewed in publications. An editorial by Feigin accompanying the second of these reviews listed what he saw as the most vitally needed information about pathogenesis and treatment of neonatal infections due to this species [8] . He referred to the important publications of the early 1970s delineating the major syndromes and posed these, at that time, unanswered questions (which I paraphrase):
1. In a relatively short time studies designed to answer each of these questions have appeared. While it is probably true that the final word on none of them is available, we have come a long way. The state of the art was recently reviewed by Baker [9] , but already the questions relating to antibiotic prophylaxis and the role of the vaginal carrier have been addressed in important newer studies. The questions numbered 4 and 5 above concern protection by transplacentally acquired antibody, the specificity of antibody, and the potency of antibody. I shall review the newer information and methodology used to answer these critical questions.
FUNCTIONAL ANTIBODY TO GROUP B STREPTOCOCCUS: IN VITRO AND ANIMAL STUDIES The presence of antibody to group B Streptococcus can be measured in the laboratory using serologic tests of primary antigen-antibody interaction such as im- [14] and in the mouse protection test when Baltimore et al.
developed the methods to enhance the virulence of GBS type III in mice [16] .
FUNCTIONAL ANTIBODY TO GROUP B STREPTOCOCCUS: HUMAN SERA At the time Baltimore et al. reported on the opsonophagocytic assay for demonstration of the antigens to which rabbit antibodies were directed [15] , Hemming and associates reported that opsonic antibody could be measured in human sera as well, using the technique of neutrophil chemiluminescence [17] . They showed that most newborns born to women colonized vaginally with GBS had serum opsonins but infants who developed sepsis or meningitis lacked opsonins in the serum. This finding has been confirmed by others, using a number of non-functional assays and with larger numbers of human subjects. One of these studies, by Baker and Kasper, measured antibody binding to the serotype III-specific carbohydrate in a RABA. The blood of mothers whose babies developed GBS infections was significantly deficient in antibody compared with the maternal blood of babies whose mothers were colonized with GBS but who escaped invasive infection [18] .
They felt that protective antibody was directed specifically to this type-specific carbohydrate. Functional assays have lent support to this thesis. Baltimore et al. demonstrated that the antigen used in this RABA absorbed out all activity of the rabbit antiserum to GBS serotype III from rabbits immunized with the whole organism [15] , and all mouse-protective activity from this serum as well [16] . These serum absorptions were serotype-specific. The RABA was "validated" as predictive of functional immunity in human sera in a demonstration of excellent correlation of antibody concentration measured by RABA and titer of opsonins [19] and mouse protection titer [20] . This A number of unanswered questions still exist. Antibody studies should be helpful in answering some of these questions. Answers to the following questions should improve our understanding of the pathogenesis of group B streptococcal infections.
1. What was responsible for the rise in incidence of group B streptococcal infection in the 1970s? Was it a change in the bacterium, the host, or the environment?
2. What is responsible for the peculiar age-specific incidence of infections due to GBS? Why is the first month of life, especially the first 48 hours, the period of such high susceptibility? 3. What is responsible for the "late-onset" infections which occur after the first week of life until several months of age? What protective mechanisms develop in the infant so that after six months of age the disease is practically never seen in childhood?
